Spineguard (ALSGD.PA) Stock Price

Spineguard Price

Euronext·CLOSED
0.09EUR-0.0042 (-4.63 %)
Market closed

Over the last 15 years Spineguard grew revenue by 2.3% annually, reaching 3.76 M EUR. For Spineguard, the net margin of -55.0% is down versus -39.2% a few years ago. The consensus 12-month price target for Spineguard is 0.44 EUR, about 394.5% above where the stock trades today. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus. The stock trades about 11% above its 52-week low.

Spineguard stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Spineguard over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Spineguard stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Spineguard's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Spineguard Stock Price History
DateSpineguard Price
8/6/20260.09 EUR
8/5/20260.09 EUR
8/4/20260.09 EUR
7/31/20260.08 EUR
7/30/20260.08 EUR
7/29/20260.08 EUR
7/28/20260.08 EUR
7/27/20260.08 EUR
7/24/20260.09 EUR
7/23/20260.09 EUR
7/22/20260.09 EUR
7/21/20260.08 EUR
7/20/20260.08 EUR
7/17/20260.08 EUR
7/15/20260.08 EUR
7/14/20260.08 EUR
7/13/20260.08 EUR
7/10/20260.08 EUR
7/9/20260.08 EUR
7/8/20260.09 EUR
7/7/20260.09 EUR
7/6/20260.08 EUR
7/3/20260.09 EUR
7/2/20260.08 EUR
7/1/20260.08 EUR
6/30/20260.08 EUR
6/29/20260.08 EUR
6/26/20260.08 EUR
6/25/20260.08 EUR
6/24/20260.09 EUR
6/23/20260.09 EUR
6/22/20260.09 EUR
6/19/20260.09 EUR
6/18/20260.09 EUR
6/17/20260.09 EUR
6/16/20260.09 EUR
6/15/20260.09 EUR
6/12/20260.09 EUR
6/11/20260.09 EUR
6/10/20260.09 EUR
6/9/20260.09 EUR
6/8/20260.09 EUR
6/5/20260.09 EUR
6/4/20260.09 EUR
6/3/20260.09 EUR
6/2/20260.09 EUR
6/1/20260.10 EUR
5/29/20260.09 EUR
5/28/20260.09 EUR
5/27/20260.09 EUR
5/26/20260.10 EUR
5/25/20260.09 EUR
5/22/20260.10 EUR
5/21/20260.10 EUR
5/20/20260.10 EUR
5/19/20260.10 EUR
5/18/20260.10 EUR
5/15/20260.10 EUR
5/14/20260.10 EUR
5/13/20260.10 EUR
5/12/20260.10 EUR
5/11/20260.10 EUR
5/8/20260.10 EUR
5/7/20260.10 EUR
5/6/20260.10 EUR
5/5/20260.10 EUR
5/4/20260.10 EUR
4/30/20260.10 EUR
4/29/20260.10 EUR
4/28/20260.10 EUR
4/27/20260.10 EUR
4/24/20260.10 EUR
4/23/20260.10 EUR
4/22/20260.10 EUR
4/21/20260.11 EUR
4/20/20260.11 EUR
4/17/20260.11 EUR
4/16/20260.11 EUR
4/15/20260.11 EUR
4/14/20260.11 EUR
4/13/20260.11 EUR
4/10/20260.11 EUR
4/9/20260.11 EUR
4/8/20260.11 EUR
4/7/20260.12 EUR
4/2/20260.12 EUR
4/1/20260.12 EUR
3/31/20260.12 EUR
3/30/20260.11 EUR
3/27/20260.12 EUR
3/26/20260.12 EUR
3/25/20260.11 EUR
3/24/20260.11 EUR
3/23/20260.12 EUR
3/20/20260.12 EUR
3/19/20260.12 EUR
3/18/20260.12 EUR
3/17/20260.12 EUR
3/16/20260.12 EUR
3/13/20260.12 EUR
3/12/20260.13 EUR
3/11/20260.12 EUR
3/10/20260.12 EUR
3/9/20260.12 EUR
3/6/20260.12 EUR
3/5/20260.12 EUR
3/4/20260.12 EUR
3/3/20260.12 EUR
3/2/20260.12 EUR
2/27/20260.12 EUR
2/26/20260.12 EUR
2/25/20260.12 EUR
2/24/20260.12 EUR
2/23/20260.13 EUR
2/20/20260.13 EUR
2/19/20260.13 EUR
2/18/20260.13 EUR
2/17/20260.13 EUR
2/16/20260.13 EUR
2/13/20260.13 EUR
2/12/20260.14 EUR
2/11/20260.12 EUR
2/10/20260.12 EUR
2/9/20260.11 EUR
2/6/20260.11 EUR
2/5/20260.11 EUR
2/4/20260.11 EUR
2/3/20260.10 EUR
2/2/20260.11 EUR
1/30/20260.11 EUR
1/29/20260.10 EUR
1/28/20260.11 EUR
1/27/20260.10 EUR
1/26/20260.11 EUR
1/23/20260.10 EUR
1/22/20260.11 EUR
1/21/20260.11 EUR
1/20/20260.11 EUR
1/19/20260.11 EUR
1/16/20260.11 EUR
1/15/20260.11 EUR
1/14/20260.11 EUR
1/13/20260.11 EUR
1/12/20260.12 EUR
1/9/20260.12 EUR
1/8/20260.11 EUR
1/7/20260.11 EUR
1/6/20260.11 EUR
1/5/20260.10 EUR
1/2/20260.09 EUR
12/31/20250.10 EUR
12/30/20250.10 EUR
12/29/20250.10 EUR
12/24/20250.10 EUR
12/23/20250.09 EUR
12/22/20250.10 EUR
12/19/20250.11 EUR
12/18/20250.10 EUR
12/17/20250.10 EUR
12/16/20250.11 EUR
12/15/20250.11 EUR
12/12/20250.12 EUR
12/11/20250.12 EUR
12/10/20250.12 EUR
12/9/20250.13 EUR
12/8/20250.15 EUR
12/5/20250.15 EUR
12/4/20250.13 EUR
12/3/20250.13 EUR
12/2/20250.13 EUR
12/1/20250.14 EUR
11/28/20250.14 EUR
11/27/20250.15 EUR
11/26/20250.16 EUR
11/25/20250.16 EUR
11/24/20250.15 EUR
11/21/20250.14 EUR
11/20/20250.14 EUR
11/19/20250.14 EUR
11/18/20250.13 EUR
11/17/20250.12 EUR
11/14/20250.11 EUR
11/13/20250.12 EUR
11/12/20250.11 EUR
11/11/20250.12 EUR
11/10/20250.12 EUR
11/7/20250.13 EUR
11/6/20250.13 EUR
11/5/20250.15 EUR
11/4/20250.12 EUR
11/3/20250.10 EUR
10/31/20250.11 EUR
10/30/20250.11 EUR
10/29/20250.12 EUR
10/28/20250.12 EUR
10/27/20250.12 EUR
10/24/20250.13 EUR
10/23/20250.13 EUR
10/22/20250.14 EUR
10/21/20250.14 EUR
10/20/20250.14 EUR
10/17/20250.14 EUR
10/16/20250.14 EUR
10/15/20250.14 EUR
10/14/20250.15 EUR
10/13/20250.13 EUR
10/10/20250.14 EUR
10/9/20250.17 EUR
10/8/20250.18 EUR
10/7/20250.15 EUR
10/6/20250.19 EUR
10/3/20250.09 EUR
10/2/20250.09 EUR
10/1/20250.09 EUR
9/30/20250.09 EUR
9/29/20250.09 EUR
9/26/20250.09 EUR
9/25/20250.09 EUR
9/24/20250.08 EUR
9/23/20250.08 EUR
9/22/20250.09 EUR
9/19/20250.08 EUR
9/18/20250.08 EUR
9/17/20250.08 EUR
9/16/20250.09 EUR
9/15/20250.08 EUR
9/12/20250.08 EUR
9/11/20250.08 EUR
9/10/20250.09 EUR
9/9/20250.08 EUR
9/8/20250.08 EUR
9/5/20250.09 EUR
9/4/20250.08 EUR
9/3/20250.08 EUR
9/2/20250.09 EUR
9/1/20250.09 EUR
8/29/20250.09 EUR
8/28/20250.09 EUR
8/27/20250.09 EUR
8/26/20250.09 EUR
8/25/20250.09 EUR
8/22/20250.09 EUR
8/21/20250.09 EUR
8/20/20250.09 EUR
8/19/20250.10 EUR
8/18/20250.10 EUR
8/15/20250.10 EUR
8/14/20250.10 EUR
8/13/20250.10 EUR
8/12/20250.10 EUR
8/11/20250.10 EUR
Access this data via the Eulerpool API
Get Free API Key

Spineguard Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
4.41 M EUR
-1.48 M EUR
-1.72 M EUR
Jan 1, 2022
5.60 M EUR
-1.56 M EUR
-2.39 M EUR
Jan 1, 2023
4.31 M EUR
-3.83 M EUR
-4.18 M EUR
Jan 1, 2024
4.65 M EUR
-3.06 M EUR
-3.08 M EUR
Jan 1, 2025
3.76 M EUR
-1.68 M EUR
-2.07 M EUR
Jan 1, 2026 (e)
3.26 M EUR
-1.65 M EUR
-939,200.00 EUR
Jan 1, 2027 (e)
3.99 M EUR
-2.02 M EUR
967,376.00 EUR
Jan 1, 2028 (e)
4.72 M EUR
-2.39 M EUR
0.00 EUR

Spineguard Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 10, 2026, 2:34 AM
 
REVENUEM EUR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM EUR
EBITM EUR
EBIT MARGIN%
NET INCOMEM EUR
NET INCOME GROWTH%
SHARESM
20132014201520162017201820192020202120222023202420252026e2027e2028e
4.004.006.007.008.007.006.004.004.005.004.004.003.003.003.004.00
33.33–50.0016.6714.29-12.50-14.29-33.33–25.00-20.00–-25.00––33.33
100.0075.0083.3385.7175.0085.7183.3375.0075.0080.0075.0075.0066.6766.6766.6766.67
4.003.005.006.006.006.005.003.003.004.003.003.002.002.002.002.67
-3.00-4.00-3.00-3.00-3.00-1.00–-1.00-1.00-1.00-3.00-3.00-1.00-1.00-2.00-2.00
-75.00-100.00-50.00-42.86-37.50-14.29–-25.00-25.00-20.00-75.00-75.00-33.33-33.33-66.67-50.00
-3.00-4.00-3.00-4.00-4.00-2.00–-2.00-1.00-2.00-4.00-3.00-2.00–––
–33.33-25.0033.33–-50.00––-50.00100.00100.00-25.00-33.33–––
4.324.384.975.025.636.6513.4024.2830.1333.9840.5147.4989.5289.5289.5289.52
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Spineguard generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Spineguard retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Spineguard's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Spineguard has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Spineguard's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Spineguard stock margins

The Spineguard margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Spineguard. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Spineguard.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
77.80 %
-33.68 %
-39.15 %
Jan 1, 2022
80.64 %
-27.84 %
-42.74 %
Jan 1, 2023
78.35 %
-88.87 %
-97.00 %
Jan 1, 2024
78.06 %
-65.83 %
-66.31 %
Jan 1, 2025
78.87 %
-44.84 %
-55.04 %
Jan 1, 2026 (e)
78.87 %
-50.67 %
-28.81 %
Jan 1, 2027 (e)
78.87 %
-50.67 %
24.25 %
Jan 1, 2028 (e)
78.87 %
-50.67 %
0.00 %

Spineguard Stock Revenue, EBIT, Earnings per Share

The Spineguard earnings per share therefore indicates how much revenue Spineguard has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.15 EUR
-0.05 EUR
-0.06 EUR
Jan 1, 2022
0.16 EUR
-0.05 EUR
-0.07 EUR
Jan 1, 2023
0.11 EUR
-0.09 EUR
-0.10 EUR
Jan 1, 2024
0.10 EUR
-0.06 EUR
-0.06 EUR
Jan 1, 2025
0.04 EUR
-0.02 EUR
-0.02 EUR
Jan 1, 2026 (e)
0.03 EUR
-0.02 EUR
-0.01 EUR
Jan 1, 2027 (e)
0.04 EUR
-0.02 EUR
0.01 EUR
Jan 1, 2028 (e)
0.05 EUR
-0.03 EUR
0.00 EUR

Spineguard business model & stock analysis

SpineGuard SA is a French company that operates in the field of medical technology. The company was founded in 2009 and is headquartered in Paris. SpineGuard is a leading provider of instruments and devices to improve the precision and effectiveness of spinal surgeries. The company focuses on developing and marketing products in the field of spinal surgery, enhancing surgical instruments and devices to assist and facilitate surgeons in performing spinal operations. SpineGuard succeeds by bringing innovative products to the market, partnering with leading orthopedic companies, and addressing customer needs. The company offers a wide range of instruments and devices for spinal surgeries, including a bone slurper, vertebral body tensioner, and pedicle shaver. It has also developed the DSG (Dynamic Surgical Guidance) technology, which provides real-time feedback to surgeons during operations, improving surgical precision and reducing the risk of complications. SpineGuard operates in three areas: instrument and device development for spinal surgery, partnerships with leading orthopedic companies, and sales and marketing. The company constantly strives to improve its products and introduce new developments to the market. In conclusion, SpineGuard is an innovative company that focuses on improving surgical instruments and devices in spinal surgery. It has established a strong presence in the medical technology market with its wide range of products and technologies. By partnering with leading orthopedic companies and utilizing a dedicated sales and marketing team, SpineGuard aims to make its products accessible to a broader audience. The company is customer-focused and continually seeks to bring innovative products to market to enhance surgical precision and effectiveness.

Spineguard SWOT Analysis

Strengths

Spineguard SA has several strengths that contribute to its success in the market. These include:

  • Strong technological expertise in spine surgery and implantable devices.
  • Patented PediGuard® technology that enhances surgical accuracy and safety.
  • Established partnerships with leading medical institutions and key opinion leaders.
  • Proven track record of successful product implementations, resulting in improved patient outcomes.
  • Strong brand reputation and recognition in the market.
  • Well-developed distribution network globally.

Weaknesses

However, Spineguard SA also faces certain weaknesses that need to be addressed to maintain its competitive position:

  • Relatively small size and limited resources compared to some larger competitors.
  • Dependency on key partnerships and relationships for product development and market penetration.
  • Sensitivity of the spine surgery market to economic fluctuations, impacting demand and sales.
  • Limited diversification of product portfolio, with a focus primarily on spine surgery solutions.

Opportunities

Spineguard SA has several opportunities to capitalize on and drive future growth:

  • Increasing global prevalence of spine-related disorders and surgeries, creating a growing market.
  • Expanding geographical presence in untapped markets, such as emerging economies.
  • Continued product innovation and development to meet evolving customer needs and preferences.
  • Strategic collaborations and partnerships to enhance market reach and access new customer segments.
  • Potential for penetrating other orthopedic specialties beyond spine surgery.

Threats

Despite its strengths, Spineguard SA faces certain threats that may hinder its growth and profitability:

  • Intense competition from larger, established competitors with significant market share.
  • Potential emergence of new technologies or surgical techniques that could render current solutions obsolete.
  • Regulatory challenges and compliance requirements for medical devices in different markets.
  • Market fluctuations and economic downturns impacting healthcare budgets and purchasing decisions.

Spineguard Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Spineguard historical P/E ratio, EBIT multiple, and P/S ratio

Spineguard annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Spineguard shares outstanding

The number of shares of Spineguard was 89.52 M in 2025. This indicates how many shares Spineguard is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
30.13 M Stocks
Jan 1, 2022
33.98 M Stocks
Jan 1, 2023
40.51 M Stocks
Jan 1, 2024
47.49 M Stocks
Jan 1, 2025
89.52 M Stocks
Jan 1, 2026 (e)
89.52 M Stocks
Jan 1, 2027 (e)
89.52 M Stocks
Jan 1, 2028 (e)
89.52 M Stocks

Current Spineguard forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
31.75 %
Buy
88.89 % (8)
Hold
11.11 % (1)
Sell
0.00 % (0)
12M Price Target
0.44
Last Price
0.09
Currency
EUR
12M Return Potential
407.05 %
LTM Return
0 %

Spineguard shareholder structure

% Name
2.41793%
Spineguard SA Management
Spineguard SA Management

Spineguard Beneficial Ownership Filings (SEC 13D/G)

Free Float
27.0%
Float Shares
-
Shares Outstanding
-

Spineguard Executives and Management Board

9 members · 33 % women

PJ

Mr. Pierre Jerome

Chairman of the Board, Chief Executive Officer, Co-Founder, Member of the Management Board · since 2009

180,026.00 EUR

Management

SB

Mr. Stephane Bette

Deputy Chief Executive Officer, Co-Founder, Member of the Management Board, Director · since 2009

133,670.00 EUR
AM

Ms. Anne-Charlotte Millard

Chief Financial Officer · since 2024

–
SM

Mr. Steve Mcadoo

General Manager, USA

–
PL

Ms. Patricia Lempereur

Vice President - International Sales & Global Marketing · since 2024

–

Board of Directors

TC

Mr. Thibault Chandanson

Director - R&D · since 2024

–
YZ

Mr. Yannis Zoughailech

Director - Quality and Regulatory Affairs

–
PB

Prof. Maurice Bourlion

Director

–
AP

Ms. Alexia Perouse

Non-Executive Director

–

Frequently asked questions about Spineguard

The business model of Spineguard SA focuses on providing innovative medical devices for spine surgery. Spineguard develops and markets tools that enhance surgical safety and accuracy during spinal procedures. The company's flagship product, DSG™ (Dynamic Surgical Guidance), is a real-time nerve detection technology that aids surgeons in avoiding potential nerve injuries. By combining cutting-edge technology with extensive medical expertise, Spineguard aims to improve patient outcomes and revolutionize spinal surgery practices. Spineguard SA's business model centers on manufacturing and commercializing these advanced surgical tools, ensuring safer and more efficient procedures for medical professionals worldwide.

Spineguard SA is primarily active in the medical technology industry.

The main competitors of Spineguard SA in the market include companies like Medtronic, NuVasive, Zimmer Biomet, and Globus Medical.

SpineGuard SA is a leading medical technology company specializing in the development and commercialization of innovative surgical solutions to make spine surgery safer and more efficient. Founded in 2009, the company is based in France and has operations globally. With a focus on real-time feedback technology, SpineGuard SA has developed a unique platform that enables surgeons to accurately and easily detect potential risks during spinal surgeries. This not only enhances patient safety but also improves surgical outcomes. SpineGuard SA has a strong commitment to research and development, constantly striving to deliver cutting-edge solutions to healthcare professionals worldwide.

Spineguard SA, a prominent medical technology company, has achieved several significant milestones. The company successfully pioneered and patented the "PediGuard" technology, a real-time nerve detection system. Spineguard's innovative system has revolutionized spine surgery by enhancing accuracy and reducing the risk of surgical complications. The company received numerous industry accolades for its groundbreaking technology, including FDA clearance and CE marking. Spineguard SA expanded its global presence by establishing partnerships with renowned medical device manufacturers. With continuous research and development, Spineguard remains dedicated to advancing spine surgery procedures and improving patient outcomes.

Spineguard SA is primarily present in various countries and regions around the world. The company's global presence extends to Europe, including France, Germany, the United Kingdom, Italy, and Spain. Additionally, Spineguard SA has a strong presence in North America, specifically in the United States and Canada. The company also operates in Asia, with a significant presence in Japan and China. With its dedication to improving spine surgery safety and innovative technologies, Spineguard SA's reach spans across multiple continents, allowing it to serve patients and healthcare professionals internationally.

Spineguard SA represents a commitment to innovation, patient safety, and improved surgical outcomes within the field of spine surgery. As a company, Spineguard focuses on developing and commercializing unique technology and products for spine surgery, offering real-time feedback and guidance to surgeons. With a strong corporate philosophy rooted in patient-centric solutions, Spineguard aims to revolutionize surgical techniques, reducing the risks associated with spinal procedures, and enhancing patient recovery. By leveraging cutting-edge technologies and expertise, Spineguard SA strives to redefine the standard of care in spine surgery, promoting the well-being and long-term outcomes for patients worldwide.

Analysts currently set an average price target of 0.44 EUR for the Spineguard stock (median: 0.44 EUR), implying +407.1 % versus the latest price. The consensus is based on 9 analyst ratings.

Spineguard Analyst Price Targets 2026

9 analysts currently rate the Spineguard stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Spineguard to generate revenue of 3.26 M EUR and earnings per share of -0.01 EUR.

Spineguard Analyst Price Targets 2026

The Spineguard share (ALSGD.PA) is listed on 4 stock exchanges, including: Frankfurt (6W5.F), München (6W5.MU), Paris (ALSGD.PA).

SpineGuard SA is a French company specializing in the development and sale of innovative medical devices used in surgical procedures to enhance safety and effectiveness. The company offers a range of products under two main categories: devices and services. Its device division includes the DSG® brand, which produces unique surgical instruments for skull and bone surgery. The DSG technology provides real-time information and feedback to surgeons regarding instrument positioning and the direction of planned operations, improving precision and effectiveness. In addition to skull and bone surgery, SpineGuard also offers solutions for specific spinal and neurosurgical applications. In its services division, SpineGuard provides training programs for surgeons and operating room staff to ensure optimal utilization of their DSG systems. The company also offers comprehensive financing solutions to ease the purchase and use of DSG systems for surgical facilities. SpineGuard's business model revolves around providing innovative solutions to support the field of surgery and medical institutions. By using DSG systems and other products from SpineGuard, surgeons are able to work more accurately and minimize risks, especially in challenging procedures. The investments in surgeon training and financial offerings help increase the penetration of SpineGuard's solutions and provide real support to customers in their daily practices. In summary, SpineGuard offers an innovative technology that enables better outcomes in surgery. The DSG technology is ideal for complex bone surgery and spinal issues and is supported by comprehensive training programs and financing options. The company aims to enhance patient safety and optimize medical processes to meet the demands of hospitals, doctors, and patients.

The expected revenue of Spineguard is 3.26 M EUR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Spineguard is -939,200.00 EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Spineguard is currently -8.45. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Spineguard stock.

The price-to-sales ratio (P/S) of Spineguard is currently 2.44. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Spineguard stock.

The Eulerpool Quality Score for Spineguard is 2/10.

The ISIN of Spineguard is FR0011464452. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Spineguard is A1T9RS. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Spineguard is ALSGD.PA. The ticker symbol is used to trade Spineguard shares on the stock exchange.

Spineguard paid dividends every year for the past 0 years.

Spineguard is assigned to the 'Health' sector.

The dividends of Spineguard are distributed in EUR.

All fundamentals and in-depth analysis of Spineguard

Our stock analysis for Spineguard stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Spineguard. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Spineguard Stock
Spineguard Revenue→
Spineguard Stock
Spineguard Net Income→
Spineguard Stock
Spineguard P/E→
Spineguard Stock
Spineguard P/S→
Spineguard Stock
Spineguard EBIT→
Spineguard Stock
Spineguard Dividend→
Spineguard Stock
Spineguard Directors Dealings→
Spineguard Stock
Spineguard Stocks→
Spineguard Stock
Spineguard Market capitalization→
Spineguard Stock
Spineguard Debt→
Spineguard Stock
Spineguard Liabilities→
Spineguard Stock
Spineguard Equity→
Spineguard Stock
Spineguard AAQS→
Spineguard Stock
Spineguard Employees→
Spineguard Stock
Spineguard ROE→
Spineguard Stock
Spineguard ROA→
Spineguard Stock
Spineguard ROCE→
Spineguard Stock
Spineguard News→
Spineguard Stock
Spineguard Analyst Price Targets→

Health Stocks

SpinewaySphereSpire Healthcare GroupSpero TherapeuticsSpirit Scientific CoSpeedusSPMSpeed Medical SAESPO GlobalSpectral MedicalSprint BioscienceSpectral AIAll Stocks A–Z →